Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
14C-PF-06826647-LR · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PF-06826647 600 mg PO>PF-06826647 600 mg PO+100 ug IV | EXPERIMENTAL | PF-06826647 600 mg single dose in Period 1 followed by PF-06826647 600 mg PO and IV infusion of 100 ug of PF-06826647 in Period 2. |
| Name | Type | Description |
|---|---|---|
| 14C-PF-06826647-LR 600 mg PO | DRUG | 14C-PF-06826647-LR 600 mg with 300 nCi orally as extemp prep |
| PF-06826647 600 mg PO | DRUG | Unlabeled PF-06826647 600 mg |
| 14C-PF-06826647 100 ug IV | DRUG | 14C-PF-06826647 100 ug IV |
Inclusion Criteria: * Healthy Male participants must be 18 to 55 years of age, inclusive. * Male participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, including BP and pulse rate measurement, laboratory tests, and 12 lead ECG. * Pa...
14C-PF-06826647-LR is a carbon-14 radiolabeled small molecule developed by Pfizer, Inc. (ticker: PFE). It was studied in healthy male participants in a Phase 1 trial to assess mass balance and absolute bioavailability. The compound is also known as 14C-PF-06826647-LR 600 mg PO.
14C-PF-06826647-LR is not a treatment for a disease. It was used as a radiolabeled tracer in a Phase 1 clinical study of healthy male volunteers to evaluate how the body processes the drug, including mass balance and absolute bioavailability.
14C-PF-06826647-LR is made by Pfizer, Inc., which trades under the ticker PFE. Pfizer is the developer responsible for the compound and the Phase 1 study conducted in the Netherlands.
14C-PF-06826647-LR is in Phase 1 development. It is an investigational radiolabeled small molecule and has been tested in a single completed Phase 1 trial. It is not approved for any indication.
14C-PF-06826647-LR was studied in one completed Phase 1 trial, NCT04591262, titled "A Study To Assess Mass Balance And Absolute Bioavailability Of 14C PF-06826647 In Healthy Male Participants." The trial enrolled 6 healthy male volunteers in the Netherlands.